Cargando…
HSP90 inhibitor AUY922 can reverse Fulvestrant induced feedback reaction in human breast cancer cells
Hormone therapy has become one of the main strategies for breast cancer, however, many estrogen receptor (ER) positive patients end in tumor collapse due to initial or acquired resistance to hormone treatment, which includes Fulvestrant. Here we report that ErbB receptors and downstream PI3K/AKT and...
Autores principales: | Bai, Jingchao, Zhou, Guanglin, Qiu, Yufan, Hu, Yunhui, Liu, Jingjing, Zhao, Jing, Zhang, Sheng, Zhang, Jin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5480065/ https://www.ncbi.nlm.nih.gov/pubmed/28301080 http://dx.doi.org/10.1111/cas.13238 |
Ejemplares similares
-
Complex Crystal Structure Determination of Hsp90(N)-NVP-AUY922 and In Vitro Anti-NSCLC Activity of NVP-AUY922
por: He, Chun-Xia, et al.
Publicado: (2022) -
Role of the novel HSP90 inhibitor AUY922 in hepatocellular carcinoma: Potential for therapy
por: CHENG, WEI, et al.
Publicado: (2015) -
Potent antitumor activity of the novel HSP90 inhibitors AUY922 and HSP990 in neuroendocrine carcinoid cells
por: ZITZMANN, KATHRIN, et al.
Publicado: (2013) -
NVP-AUY922, a novel HSP90 inhibitor, inhibits the progression of malignant pheochromocytoma in vitro and in vivo
por: Lian, Jianpo, et al.
Publicado: (2017) -
Reactivation of ERK and Akt confers resistance of mutant BRAF colon cancer cells to the HSP90 inhibitor AUY922
por: Wang, Chun Yan, et al.
Publicado: (2016)